Zymeworks (ZYME) 10-Q 5 Nov 19 2019 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2019	Oct. 31, 2019
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Registrant Name	Zymeworks Inc.
Trading Symbol	ZYME
Entity Central Index Key	0001403752
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Address, State or Province	BC
Entity Ex Transition Period	true
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Shares
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		39,387,339

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 250,844	$ 42,205
Short-term investments (note 4)	84,259	157,959
SR&ED receivables	95	997
Accounts receivables	3,325	358
Prepaid expenses and other current assets	6,788	2,850
Total current assets	345,311	204,369
Deferred financing fees		265
Acquired in-process research and development (note 5)	17,628	18,396
Goodwill (note 5)	12,016	12,016
Long-term prepaid assets	2,278	1,135
Property and equipment, net	10,148	6,484
Operating lease right-of-use assets	5,443
Intangible assets, net	6,958	1,614
Deferred tax assets	255	84
Total assets	400,037	244,363
Current liabilities:
Accounts payable and accrued liabilities (note 6)	26,922	13,403
Fair value of liability classified options	22,846	12,603
Current portion of operating lease liability (note 9)	912
Current portion of deferred revenue (note 8)		3,530
Other current liabilities (note 6)	9	450
Total current liabilities	50,689	29,986
Long-term portion of operating lease liability (note 9)	5,843
Long-term portion of deferred revenue (note 8)	32,941	32,941
Other long-term liabilities (note 6)	1,039	946
Total liabilities	90,512	63,873
Shareholders' equity:
Common shares, no par value; unlimited authorized shares at September 30, 2019 and December 31, 2018, respectively; 39,335,992 and 31,977,668 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively (note 7a)	444,439	320,074
Additional paid-in capital	90,210	12,347
Accumulated other comprehensive loss	(6,659)	(6,659)
Accumulated deficit	(218,465)	(145,272)
Total shareholders' equity	309,525	180,490
Total liabilities and shareholders' equity	$ 400,037	$ 244,363

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common shares, authorized	Unlimited	Unlimited
Common shares, no par value	$ 0	$ 0
Common shares, issued	39,335,992	31,977,668
Common shares, outstanding	39,335,992	31,977,668

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue
Research and development collaborations (note 8)		$ 7,860	$ 2,054	$ 27,667	$ 24,094
Operating expenses
Research and development		29,251	14,195	70,511	42,648
General and administrative		12,173	7,447	33,937	23,161
Impairment on acquired IPR&D (note 5)				768
Total operating expenses		41,424	21,642	105,216	65,809
Loss from operations		(33,564)	(19,588)	(77,549)	(41,715)
Other income (expense):
Interest and other expense		(33)	(166)	(90)	(166)
Change in fair value of warrant liabilities					(3,565)
Interest and other income		2,097	1,131	4,566	1,648
Foreign exchange (loss) gain		117	(79)	(200)	(205)
Total other income (expense), net		2,181	886	4,276	(2,288)
Loss before income taxes		(31,383)	(18,702)	(73,273)	(44,003)
Current income tax recovery (expense)		710	(168)	(171)	(2,000)
Deferred income tax recovery		198	119	251	174
Net loss and comprehensive loss		$ (30,475)	$ (18,751)	$ (73,193)	$ (45,829)
Net loss per common share (note 2):
Basic		$ (0.70)	$ (0.59)	$ (2.03)	$ (1.63)
Diluted		$ (0.70)	$ (0.59)	$ (2.03)	$ (1.63)
Weighted-average common shares outstanding (note 2):
Basic	[1]	43,445,379	31,959,206	36,143,113	28,119,872
Diluted		43,445,379	31,959,206	36,143,113	28,119,872
[1]	Weighted average number of common shares used in the basic earnings per share calculation for the three and nine months ended September 30, 2019 includes the pre-funded warrants issued in connection with the Company’s June 2019 offering as the warrants are exercisable at any time and for nominal cash consideration.

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholders' Equity - USD ($) $ in Thousands	Total	Common Shares [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Additional Paid-in Capital [Member]
Beginning balance at Dec. 31, 2017	$ 116,428	$ 222,991	$ (108,716)	$ (6,659)	$ 8,812
Beginning balance, shares at Dec. 31, 2017		25,444,006
Issuance of common shares on exercise of options	34	$ 56			(22)
Issuance of common shares on exercise of options, shares		7,207
Issuance of common shares through employee share purchase plan	100	$ 100
Issuance of common shares through employee share purchase plan, shares		13,247
Stock-based compensation	(830)				(830)
Net Loss	(21,204)		(21,204)
Ending balance at Mar. 31, 2018	94,528	$ 223,147	(129,920)	(6,659)	7,960
Ending balance, shares at Mar. 31, 2018		25,464,460
Beginning balance at Dec. 31, 2017	116,428	$ 222,991	(108,716)	(6,659)	8,812
Beginning balance, shares at Dec. 31, 2017		25,444,006
Net Loss	(45,829)
Ending balance at Sep. 30, 2018	169,670	$ 319,890	(154,545)	(6,659)	10,984
Ending balance, shares at Sep. 30, 2018		31,962,680
Beginning balance at Mar. 31, 2018	94,528	$ 223,147	(129,920)	(6,659)	7,960
Beginning balance, shares at Mar. 31, 2018		25,464,460
Issuance of common shares on exercise of options	602	$ 874			(272)
Issuance of common shares on exercise of options, shares		69,620
Stock-based compensation	1,517				1,517
Issuance of common shares on exercise of warrants	4,913	$ 4,913
Issuance of common shares on exercise of warrants, shares		206,361
Issuance of common shares and warrants in connection with public offering	90,779	$ 90,779
Issuance of common shares and warrants in connection with public offering, shares		6,210,000
Net Loss	(5,874)		(5,874)
Ending balance at Jun. 30, 2018	186,465	$ 319,713	(135,794)	(6,659)	9,205
Ending balance, shares at Jun. 30, 2018		31,950,441
Issuance of common shares on exercise of options	47	$ 52			(5)
Issuance of common shares on exercise of options, shares		2,997
Issuance of common shares through employee share purchase plan	152	$ 152
Issuance of common shares through employee share purchase plan, shares		9,242
Stock-based compensation	1,784				1,784
Issuance of common shares and warrants in connection with public offering	(27)	$ (27)
Net Loss	(18,751)		(18,751)
Ending balance at Sep. 30, 2018	169,670	$ 319,890	(154,545)	(6,659)	10,984
Ending balance, shares at Sep. 30, 2018		31,962,680
Beginning balance at Dec. 31, 2018	$ 180,490	$ 320,074	(145,272)	(6,659)	12,347
Beginning balance, shares at Dec. 31, 2018	31,977,668	31,977,668
Issuance of common shares on exercise of options	$ 419	$ 549			(130)
Issuance of common shares on exercise of options, shares		52,130
Issuance of common shares through employee share purchase plan	325	$ 325
Issuance of common shares through employee share purchase plan, shares		18,681
Fair value adjustments upon reclassification of options to liabilities	(119)				(119)
Stock-based compensation	2,533				2,533
Net Loss	(13,641)		(13,641)
Ending balance at Mar. 31, 2019	170,007	$ 320,948	(158,913)	(6,659)	14,631
Ending balance, shares at Mar. 31, 2019		32,048,479
Beginning balance at Dec. 31, 2018	$ 180,490	$ 320,074	(145,272)	(6,659)	12,347
Beginning balance, shares at Dec. 31, 2018	31,977,668	31,977,668
Net Loss	$ (73,193)
Ending balance at Sep. 30, 2019	$ 309,525	$ 444,439	(218,465)	(6,659)	90,210
Ending balance, shares at Sep. 30, 2019	39,335,992	39,335,992
Beginning balance at Mar. 31, 2019	$ 170,007	$ 320,948	(158,913)	(6,659)	14,631
Beginning balance, shares at Mar. 31, 2019		32,048,479
Issuance of common shares on exercise of options	2,044	$ 2,285			(241)
Issuance of common shares on exercise of options, shares		115,298
Stock-based compensation	3,038				3,038
Issuance of common shares and warrants in connection with public offering	188,005	$ 117,941			70,064
Issuance of common shares and warrants in connection with public offering, shares		7,013,892
Net Loss	(29,077)		(29,077)
Ending balance at Jun. 30, 2019	334,017	$ 441,174	(187,990)	(6,659)	87,492
Ending balance, shares at Jun. 30, 2019		39,177,669
Issuance of common shares on exercise of options	2,235	$ 2,827			(592)
Issuance of common shares on exercise of options, shares		133,696
Issuance of common shares through employee share purchase plan	438	$ 438
Issuance of common shares through employee share purchase plan, shares		24,627
Stock-based compensation	3,310				3,310
Net Loss	(30,475)		(30,475)
Ending balance at Sep. 30, 2019	$ 309,525	$ 444,439	$ (218,465)	$ (6,659)	$ 90,210
Ending balance, shares at Sep. 30, 2019	39,335,992	39,335,992

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Loss for the period	$ (73,193)	$ (45,829)
Items not involving cash:
Depreciation and amortization of property and equipment	1,573	1,400
Amortization of intangible assets	2,156	1,094
Impairment of acquired IPR&D	768
Stock-based compensation	20,965	11,943
Amortization of operating lease right-of-use assets	1,019
Deferred income tax expense (recovery)	(171)	(174)
Change in fair value of warrant liabilities		3,565
Change in fair value of contingent consideration	285	53
Unrealized foreign exchange loss	152	254
Changes in non-cash operating working capital:
Accounts receivable	(2,967)	(15)
SR&ED receivables	902	1,088
Prepaid expenses and other current assets	(5,567)	(280)
Accounts payable and accrued liabilities	12,449	1,018
Operating lease liabilities	(41)
Deferred revenue	(3,530)
Income taxes payable	(299)	(45)
Net cash used in operating activities	(45,499)	(25,928)
Cash flows from financing activities:
Proceeds from public offering, net of issuance costs (note 1 and 7c)	188,231	90,752
Issuance of common shares on exercise of options (note 7d)	2,687	581
Issuance of common shares through employee share purchase plan	598	252
Finance lease payments	(13)	(8)
Net cash from financing activities	191,503	91,577
Cash flows from investing activities:
Short-term investments	74,286	(69,881)
Acquisition of property and equipment	(4,181)	(544)
Acquisition of intangible assets	(7,500)	(2,607)
Net cash from (used in) investing activities	62,605	(73,032)
Effect of exchange rate changes on cash and cash equivalents	30	(188)
Net change in cash and cash equivalents	208,639	(7,571)
Cash and cash equivalents, beginning of period	42,205	35,946
Cash and cash equivalents, end of period	250,844	28,375
Supplemental disclosure of non-cash investing and finance items:
Leased assets obtained in exchange for operating lease liabilities	6,682
Share issue costs and deferred financing fees in accounts payable and accrued liabilities		153
Acquisition of property and equipment in accounts payable and accrued liabilities	$ 1,056	63
Cashless exercise of warrants		$ 4,913

Nature of Operations

Nature of Operations	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	1. Nature of Operations Zymeworks (the “Company” or “Zymeworks”) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks was incorporated on September 8, 2003 Since its inception, the Company has devoted substantially all of its resources to research and development activities, including developing its therapeutic platforms, identifying and developing potential product candidates by undertaking preclinical studies and clinical trials. The Company supports these activities through general and administrative support, as well as by raising capital, conducting business planning and protecting its intellectual property. Public Offering On January 31, 2019, the Company’s U.S. shelf registration statement on Form S-3 No. 333-228782) On June 18, 2019, the Company filed with the SEC, as well as with the securities commissions or similar securities regulatory authorities in each of the provinces and territories of Canada, a preliminary prospectus supplement to complete an underwritten public offering of its common shares and pre-funded pre-funded The Offering closed on June 24, 2019 pursuant to which the Company sold 7,013,892 shares of common shares including the sale of 1,458,336 shares of common shares to the underwriters upon their full exercise of their over-allotment option and 4,166,690 pre-funded .

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited financial statements and notes for the year ended December 31, 2018. These unaudited interim financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and nine months ended September 30, 2019 and 2018 are not necessarily indicative of results that can be expected for a full year. These unaudited interim financial statements follow the same significant accounting policies as those described in the notes to the audited financial statements of the Company for the year ended December 31, 2018, except for the new accounting guidance adopted during the period (note 3 ). Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. All amounts expressed in the interim condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for per share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” are to Canadian dollars. Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. In preparing these interim condensed consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, some of which are those related to revenue recognition including estimated timing of completion of performance obligations required to meet revenue recognition criteria, Scientific Research and Experimental Development (“SR&ED”) Program, stock-based compensation, warrants, accrual of expenses, preclinical study accruals, valuation allowance for deferred taxes, other contingencies and valuation of assets acquired in a business combination. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates. Fair Value Measurements The Company measures certain financial instruments and other items at fair value. To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows: • Level 1 inputs are quoted market prices for identical instruments available in active markets. • Level 2 inputs are inputs other than Level 1 prices, such as prices for similar asset or liability that are observable either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets. • Level 3 inputs are unobservable inputs for the asset or liability and will reflect management’s assumptions about market assumptions that would be used to price the asset or liability. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s financial instruments consist of cash and cash equivalents, short-term investments, amounts receivable, accounts payable and accrued liabilities, finance and operating The carrying values of cash and cash equivalents, short-term investments, amounts receivable and accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments. As quoted prices for the liability classified stock options are not readily available, the Company has used a Black-Scholes pricing model to estimate fair value, which utilizes level 3 inputs as defined above. Other long-term liabilities for contingent consideration related to business acquisitions are recorded at fair value on the acquisition date and adjusted quarterly for changes in its fair value. Changes in the fair value of contingent consideration liabilities can result from changes in anticipated milestone payments and changes in assumed discount periods and rates. These inputs are unobservable in the market and therefore categorized as level 3 inputs as defined above. The following tables present information about the Company’s liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value: September 30, Level 1 Level 2 Level 3 Liabilities Liability classified stock options $ 22,846 $ — $ — $ 22,846 Liability for contingent consideration (note 10) 992 — — 992 Total $ 23,838 $ — $ — $ 23,838 December 31, Level 1 Level 2 Level 3 Liabilities Liability classified stock options $ 12,603 $ — $ — $ 12,603 Liability for contingent consideration (note 10) 707 707 Total $ 13,310 $ — $ — $ 13,310 The following table presents the changes in fair value of the liability classified stock options: Liability at Reclassification to Increase (decrease) in Exercise of Unrealized foreign Liability at end of Three months ended September 30, 2019 $ 20,127 $ — $ 3,687 $ (796 ) $ (172 ) $ Nine months ended September 30, 2019 $ 12,603 $ 119 $ 11,850 $ (2,009 ) $ 283 $ 22,846 The following table presents the changes in fair value of the Company’s liability for contingent consideration: Liability at Increase (decrease) in Liability at end Three months ended September 30, 2019 $ 992 $ — $ 992 Nine months ended September 30, 2019 $ 707 $ 285 $ 992 Net loss per share Basic net loss per share attributable to common shareholders is computed by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to common shareholders is computed by adjusting net loss attributable to common shareholders to reallocate undistributed earnings based on the potential impact of dilutive securities, including stock options and warrants. Diluted net loss per share attributable to common shareholders is computed by dividing the diluted net loss attributable to common shareholders by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding instruments. ASC 260 “Earnings Per Share” requires an adjustment to the numerator for any income or loss related to ASC 815 liability classified warrants and stock options, if dilutive, if they are presumed to be share settled. The stock options outstanding were excluded from the calculation of diluted loss per share because their inclusion would have been anti-dilutive. Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Numerator: Net loss attributable to common shareholders: Basic $ (30,475 ) $ (18,751 ) $ (73,193 ) $ (45,829 ) Diluted $ (30,475 ) $ (18,751 ) $ (73,193 ) $ (45,829 ) Denominator: Weighted-average common shares outstanding: Basic (*) 43,445,379 31,959,206 36,143,113 28,119,872 Diluted 43,445,379 31,959,206 36,143,113 28,119,872 Net loss per common share—basic $ (0.70 ) $ (0.59 ) $ (2.03 ) $ (1.63 ) Net loss per common share—diluted $ (0.70 ) $ (0.59 ) $ (2.03 ) $ (1.63 ) (*): Weighted average number of common shares used in the basic earnings per share calculation for the three and nine months ended September 30, 2019 includes the pre-funded warrants issued in connection with the Company’s June 2019 offering as the warrants are exercisable at any time and for nominal cash consideration.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2019
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	3. Recent Accounting Pronouncements Initial adoption of new accounting pronouncements Adoption of Topic 842 (Leases) On January 1, 2019 the Company adopted Topic 842 using the modified retrospective approach with a cumulative-effect adjustment to accumulated deficit as of January 1, 2019 in accordance with ASU No. 2018-11, Leases (Topic 842) Leases non-lease The impact of the adoption of Topic 842 on the accompanying Condensed Consolidated Balance Sheet as of January 1, 2019 was as follows: Operating lease right-of-use (1) $ — $ 3,222 $ 3,222 Total lease inducements (2) 333 (333 ) — Total operating lease liabilities (3) — 3,561 3,561 (1) Right-of-use Right-of-use (2) Included in current and long-term other liabilities (note 6) (3) Includes current and non-current The adjustments due to the adoption of Topic 842 primarily related to the recognition of operating lease right-of-use The Company evaluated its facility leases and determined that, effective upon the adoption of Topic 842, they were all operating leases. The Company performed an evaluation of its other contracts with customers and suppliers in accordance with Topic 842 and determined that, except for the facility and equipment leases described above, none of its contracts contain a lease. The impact of the adoption of Topic 842 on the accompanying Condensed Consolidated Statements of Operations for three and nine months ended September 30, 2019 were as follows: As Effect of Balances Operating expenses for the three months ended September 30, 2019 $ 41,424 $ 158 $ 41,266 Operating expenses for the nine months ended September 30, 2019 $ 105,216 $ 408 $ 104,808 See “note 9. Leases” in these consolidated financial statements for additional disclosures. Adoption of other pronouncements In June 2018, the FASB issued ASU 2018–07, Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The amendments in this ASU expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. This new guidance is effective for the Company in fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted this standard as of January 1, 2019. Adoption of this new accounting standard did not have any significant impact on the Company’s consolidated financial statements. Recent accounting pronouncements not yet adopted In August 2018, the FASB issued ASU 2018–13, Fair Value Measurement (Topic 820): Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this ASU eliminate, add and modify certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for the Company in fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact the adoption of the standard will have on its consolidated financial statements. In August 2018, the FASB issued ASU 2018–15, Intangibles — Goodwill and Other — Internal Use Software (Subtopic 350–40). This ASU addresses customer’s accounting for implementation costs incurred in a cloud computing arrangement that is a service contract and also adds certain disclosure requirements related to implementation costs incurred for internal-use internal-use internal-use The Company has reviewed other recent accounting pronouncements and concluded that they are either not applicable to the business, or that no material effect is expected on the consolidated financial statements as a result of future adoption .

Short-Term Investments

Short-Term Investments	9 Months Ended
	Sep. 30, 2019
Investments, All Other Investments [Abstract]
Short-Term Investments	4. Short-Term Investments Short-term investments consist of guaranteed investment certificates (“GICs”) and term deposits held at financial institutions in accordance with the Company’s treasury policy. These GICs and term deposits bear interest rates of 2%-3%

IPR&D and Goodwill

IPR&D and Goodwill	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
IPR&D and Goodwill	5. IPR&D and Goodwill Acquired IPR&D All in-process During the nine months ended September 30, 2019 co-development Acquired IPR&D Net Balance at December 31, 2018 $ 20,700 $ (2,304 ) $ 18,396 Change during the period — (768 ) (768 ) Balance at September 30, 2019 $ 20,700 $ (3,072 ) $ 17,628 The Company concluded that there were no further impairment indicators related to IPR&D as of September 30, 2019. Goodwill The Company concluded that there were no impairment indicators related to goodwill as of September 30, 2019 .

Liabilities

Liabilities	9 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
Liabilities	6. Liabilities Accounts payable and accrued expenses consisted of the following: September 30, December 31, Trade payables $ 8,040 $ 2,599 Accrued research expenses 13,589 6,633 Employee compensation and vacation accruals 3,430 2,926 Accrued legal and professional fees 1,036 556 Other 827 689 Total $ 26,922 $ 13,403 Other current liabilities consisted of the following: September 30, December 31, Current income tax liability $ — $ 299 Current portion of lease inducements — 136 Current portion of finance lease liability (note 9) 9 15 Total $ 9 $ 450 Other long-term liabilities consisted of the following: September 30, December 31, Liability for contingent consideration (note 10) $ 992 $ 707 Lease inducements — 197 Finance lease liability (note 9) 47 42 Total $ 1,039 $ 946

Redeemable Convertible Class A

Redeemable Convertible Class A Preferred Shares, and Shareholders' Equity	9 Months Ended
	Sep. 30, 2019
Federal Home Loan Banks [Abstract]
Redeemable Convertible Class A Preferred Shares, and Shareholders' Equity	7. Redeemable Convertible Class A Preferred Shares, and Shareholders’ Equity The number of shares and per share amounts are presented in actual amounts. a. Authorized On May 2, 2017, the Company’s new Articles of Incorporation were issued under which the Company has an unlimited number of voting Common Shares and Preferred Shares without par value. Under the Company’s former Articles of Incorporation dated December 21, 2015, the Company had 6,413,265 authorized Redeemable Convertible Class A Preferred Shares. b. Preferred Shares As of September 30, 2019 and December 31, 2018, no preferred shares were issued or outstanding, respectively. The rights and preferences of the unissued preferred shares are as follows: Holders of Preferred Shares will be entitled to preference with respect to payment of dividends over the common shares and any other shares ranking junior to the preferred shares with respect to payment of dividends. In the event of the liquidation, dissolution or winding-up The preferred shares may also be given such other preferences over the common shares and any other shares ranking junior to the preferred shares as may be fixed by directors’ resolution as to the respective series authorized to be issued. c. Pre-funded On June 24, 2019, the Company completed a public offering of 7,013,892 common shares at $18.00 per share as well as issued pre-funded pre-funded As the Warrants meet the conditions for equity classification, proceeds from issuance of the Warrants, net of any transaction costs, are recorded in the additional paid-in paid-in d. Stock-Based Compensation Original Stock Option Plan: On July 14, 2006, the shareholders approved an employee stock option plan (the “Original Plan”). The Original Plan provides for the granting of options to directors, officers, employees and consultants. Options to purchase common shares may be granted at an exercise price of each option equal to the last private issuance of common shares immediately preceding the date of the grant. The total number of options outstanding is not to exceed 20% of the issued common shares of the Company. Options granted under the Original Plan are exercisable at various dates over their ten-year Options issued to employees under the Original Plan vest over 4 years. Options issued to directors under the Original Plan vest over 3 years, and options issued to consultants and members of the Scientific Advisory Board under the Original Plan vest immediately upon issuance. The exercise prices of the Company’s stock options are denominated in Canadian dollars. The U.S. dollar amounts have been translated using the period end rate or the average rate for the period, as applicable, and have been provided for information purposes. Upon the effectiveness of the Company’s New Stock Option Plan described below, no further options were issuable under the Original Plan. However, all outstanding options granted under the Original Plan remain outstanding, subject to the terms of the Original Plan and the applicable grant documents, until such outstanding options are exercised or they terminate or expire by their terms. New Stock Option Plan: On April 10, 2017, the Company’s shareholders approved a new stock option plan, which became effective immediately prior to the consummation of the IPO. This plan allowed for the grant of options to directors, officers, employees and consultants in U.S. or Canadian dollars, and also permitted the Company to grant incentive stock options (“ISOs”), within the meaning of Section 422 of the Code, to its employees. On June 7, 2018, the Company’s shareholders approved an amendment and restatement of this plan (this plan, as amended and restated, the “New Plan”), which includes an article that allows the Company to grant restricted shares, restricted share units (“RSU”) and other share-based awards, in addition to options. All restricted share, RSU or other share-based award terms and conditions will be specified in future grant agreements. To date, no restricted shares, RSUs or other share-based awards have been granted. The maximum number of common shares reserved for issuance under the New Plan is 5,686,097, which includes 3,985,768 shares issuable upon exercise of options outstanding as of December 31, 2018. Beginning in 2019 and ending in 2028, this maximum number may be increased on the first day of each calendar year by up to 4.0% of the number of outstanding shares on the last day of the immediately preceding calendar year. ISOs may be granted with respect to a maximum fixed amount equal to 20% of the shares reserved for issuance under the New Plan as of June 7, 2018. All options granted under the New Plan will have an exercise price determined and approved by the Board on the date of the grant, which shall not be less than the market price of the common shares at such time. For the purposes of the New Plan, the market price of a common share shall be the closing sale price of a share on the grant date reported by the stock exchange with the greatest trading volume or, if such day is not a trading day, the closing sale price reported for the immediately preceding trading day. The Company may convert a market price denominated in Canadian currency into United States currency and vice versa and such converted amount shall be the market price. An option shall be exercisable during a period established by the Board which shall commence on the date of the grant and shall terminate not later than ten years after the date of the granting of the option. The New Plan provides that the exercise period shall automatically be extended if the date on which it is scheduled to terminate shall fall during a black-out black-out The following table summarizes the Company’s stock options granted in Canadian dollars under the Original Plan and the New Plan: Number Weighted- Weighted- Weighted- Aggregate Aggregate Outstanding, December 31, 2018 2,445,990 14.66 10.74 6.99 14,421 10,571 Granted 322,800 21.34 15.91 Exercised (241,906 ) 10.60 7.97 Forfeited (37,906 ) 17.45 13.18 Outstanding, September 30, 2019 2,488,978 15.88 11.99 6.86 42,215 31,883 The following table summarizes the Company’s stock options granted in U.S. dollars under the New Plan: Number Weighted- Weighted- Aggregate Outstanding, December 31, 2018 1,539,778 11.67 9.02 4,876 Granted 1,210,050 17.07 Exercised (59,218 ) 12.94 Forfeited (30,261 ) 15.52 Outstanding, September 30, 2019 2,660,349 14.05 8.79 28,659 During the nine months ended September 30, 2019, the Company received cash proceeds of $2,686 (C$3,267) from stock options exercised. The stock options expire at various dates from September 30, 2019 September 16, 2029 The estimated fair value of options granted to officers, directors, employees and consultants is amortized over the vesting period. Stock-based compensation expense for equity classified instruments, as well as the financial statement impact of the periodic revaluation of liability classified equity instruments (note 2), is recorded in research and development expenses, general and administration expenses and finance expense (income) as follows: Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Research and development expenses: Stock-based compensation for equity classified instruments $ 1,690 $ 691 $ 4,324 $ 1,724 Change in fair value of liability classified equity instruments 888 496 2,856 1,966 $ 2,578 $ 1,187 $ 7,180 $ 3,690 General and administrative expenses: Stock-based compensation for equity classified instruments $ 1,721 $ 1,093 $ 4,791 $ 2,758 Change in fair value of liability classified equity instruments 2,781 1,304 8,908 5,342 $ 4,502 $ 2,397 $ 13,699 $ 8,100 Finance expenses: Stock-based compensation for equity classified instruments $ — $ — $ — $ 1 Change in fair value of liability classified equity instruments 18 39 86 152 $ 18 $ 39 $ 86 $ 153 The estimated fair value of stock options granted in Canadian dollars under the Original Plan and the New Plan was determined using the Black-Scholes option pricing model with the following weighted-average assumptions: Nine Months Ended September 30, 2019 2018 Dividend yield 0% 0% Expected volatility 73.74% 66.0% Risk-free interest rate 1.46% 2.17% Expected average life of options 6.05 years 5.91 years The estimated fair value of stock options granted in U.S. dollars under the New Plan was determined using the Black-Scholes option pricing model with the following weighted-average assumptions: Nine Months Ended September 30, 2019 2018 Dividend yield 0% 0% Expected volatility 72.91% 66.0% Risk-free interest rate 2.36% 2.64% Expected average life of options 6.02 years 5.87 years Expected Volatility Risk-Free Interest Rate Expected Term ten years Share Fair Value The weighted-average Black-Scholes option pricing assumptions for liability classified stock options are as follows: September 30, September 30, Dividend yield 0% 0% Expected volatility 72.8% 66.5% Risk-free interest rate 1.47% 1.55% Expected average option term 3.56 years 5.89 years Number of liability classified stock options outstanding 1,327,334 1,441,163 At September 30, 2019, the unamortized compensation expense related to unvested options was $14,276 (C$18,905). The remaining unamortized compensation expense as of September 30, 2019 will be recognized over a weighted-average period of 1.74 years. e. Employee Stock Purchase Plan: On April 10, 2017, the employee stock purchase plan, (ESPP), was approved by the shareholders of the Company and became effective immediately prior to the consummation of the IPO. On June 7, 2018, certain amendments to the ESPP were approved by shareholders. Prior to these amendments, the ESPP allowed eligible employees to acquire common shares at a discounted purchase price of 85 85 The ESPP is implemented through a series of offerings under which eligible employees are granted rights to purchase the Company’s common shares at the end of specified purchase periods at a discounted purchase price. The Company currently holds offerings consisting of a single six-month six-month Eligible employees are able to contribute up to 15% of their gross base earnings for purchases under the ESPP through regular payroll deductions. Purchases of shares under the ESPP are limited for each employee at $25 worth of the Company’s common shares (determined using the lesser of (i) the market price of a common share on the first day of the applicable purchase period and (ii) the market price of a common share on the purchase date) for each year such purchase right is outstanding. Common shares purchased under the ESPP will be issued from treasury at a purchase price equal to 85% of the applicable market price of a common share, all in accordance with applicable laws and the terms and conditions of the ESPP. For the purposes of the ESPP, the market price of a common share is defined as the closing sale price of a share on such date reported by the stock exchange with the greatest trading volume or, if such day is not a trading day, the closing sale price reported for the immediately preceding trading day. The number of common shares reserved for issuance under the ESPP shall not exceed 272,350 common shares, plus the number of common shares that are automatically added on January 1st of each year, commencing on (and including) January 1, 2018 and ending on (and including) January 1, 2027, in an amount equal to the lesser of (i) 1% of the total number of common shares issued and outstanding on December 31st of the preceding calendar year, and (ii) 419,000 common shares. As this plan is considered compensatory, a charge of $232 has been recorded to research and development expense and general and administrative expense accounts. As of September 30, 2019, total amount contributed by the ESPP participants is $223. The Company recognizes compensation expense on these awards based on their estimated grant date fair value using the Black-Scholes option pricing model. The Company recognizes compensation expense in the consolidated statements of loss and comprehensive loss on a straight-line basis over the requisite service period.

Research, Collaboration and Lic

Research, Collaboration and Licensing Agreements	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Research, Collaboration and Licensing Agreements	8. Research, Collaboration and Licensing Agreements In accordance with ASC 606, the Company recognizes revenue when the Company’s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised deliverables in the contract; (ii) determination of whether the promised deliverables are performance obligations including whether they are distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on the stand-alone selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration that it is entitled to in exchange for the goods and services transferred to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, to identify distinct performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (“ASC 808”), the Company applies the revenue recognition model under ASC 606 to part or all of the arrangement, when deemed appropriate. The Company has entered into a number of collaboration and licensing agreements. Promised deliverables within these agreements may include: (i) grants of licenses, or options to obtain licenses, to the Company’s intellectual property, (ii) research and development services, (iii) drug product manufacturing, and (iv) participation on joint research and/or development committees. The terms of these agreements typically include one or more of the following types of payments to the Company: • non-refundable, • research, development and regulatory milestone payments; • commercial milestone payments; and • royalties on net sales of licensed products. Licenses of intellectual property including platform technology access: non-refundable, non-refundable, Milestone payments: re-evaluates catch-up Research and development milestones in the Company’s collaboration agreements may include some, but not necessarily all, of the following types of events: • completion of preclinical research and development work leading to selection of product candidates; • initiation of Phase 1, Phase 2 and Phase 3 clinical trials; and • achievement of certain other technical, scientific or development criteria. Regulatory milestone payments may include the following types of events: • filing of regulatory applications for marketing approval in the United States, Europe or Japan, including Investigational New Drug (“IND”) applications and Biologics License Application (“BLA”); and • marketing approval in major markets, such as the United States, Europe or Japan. Royalties and commercial milestones: pre-specified out-licensing Research support payments: If the expectation at contract inception is such that the period between payment by the licensee and the completion of related performance obligations will be one year or less, the Company assumes that the contract does not have a significant financing component. Strategic Partnership Revenue The following table presents summarized revenue recognized from the Company’s strategic partnerships. Three Months Ended Nine Months Ended 2019 2018 2019 2018 BeiGene: Recognition of upfront fee $ — $ — $ 3,530 $ — Lilly: Milestone revenue — 2,000 8,000 2,000 Daiichi Sankyo: Upfront technology access fee — — — 18,000 Commercial license option fee — — 3,500 — LEO: Research support payments 336 — 1,108 — Celgene: Option exercise fee 7,500 — 7,500 4,000 Merck: Milestone revenue — — 2,000 — Iconic: Milestone revenue — — 1,000 — Research support and supplies payments 24 — 1,029 — Other: Research support payments — 54 — 94 $ 7,860 $ 2,054 $ 27,667 $ 24,094 As at September 30, 2019 and December 31, 2018, contract assets from research, collaboration and licensing agreements were $nil. Contract liabilities are comprised of $ 32,941 36,471 Research and License Agreement with Merck Sharp & Dohme Research Ltd. (“Merck”) On August 22, 2011, the Company entered into a Research and License Agreement with Merck providing Merck a worldwide license to develop and commercialize novel bispecific antibodies generated through use of the Company’s Azymetric platform toward certain exclusive therapeutic targets. Both companies will collaborate to advance the therapeutic platforms, with Merck working to progress the bispecific therapeutic antibody candidates through clinical development and commercialization. No joint development activities to advance the therapeutic platforms have occurred since inception and Merck no longer has a right to such joint activities. In 2013, Merck was also provided with a limited, non-exclusive On December 3, 2014, the Company and Merck jointly amended the agreement, including amending certain terms and exclusivities contained therein. Under the terms of the amended agreement, the Company receives funding for certain internal and external research costs incurred in the project. Additionally, the amendment removed a $2.0 million research milestone from the total milestones the Company would be eligible to receive over the life of the agreement. The new research funding terms were priced at market rate, and the Company concluded that the original agreement was not materially modified. Accordingly, the amendments did not impact the determination of units of accounting or the allocation of the arrangement consideration. Upon the execution of the agreement, the Company received a one-time, non-refundable IND-enabling The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Merck, is a customer. The Company identified the following promised goods and services at the inception of the Merck agreement: (1) the research license, (2) the commercial license, (3) the transfer of the Company’s platform technology (Azymetric) (4) research services and technical assistance in connection with the transfer of platform technology to Merck, and (5) research activities to be performed on behalf of Merck. The Company concluded that the licenses and platform technologies together are distinct. Accordingly, the deliverables (1) through (4) were considered as a single performance obligation and the upfront payment of $ 1.25 know-how In order to evaluate the appropriate transaction price, the Company determined that the upfront amount constituted the entirety of the consideration to be included in the transaction price and to be allocated to the performance obligations based on the Company’s best estimate of their relative stand-alone selling prices. The Company estimated the best estimate of selling price of the licenses and technology platform based on comparable license and collaboration arrangements. The best estimate of selling price for the other deliverables was estimated using internal estimates of cost to perform the specific services plus a normal profit margin for providing the services. At execution, the transaction price included only the $1.25 million upfront consideration received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Merck and therefore have also been excluded from the transaction price. The Company will re-evaluate The consideration otherwise allocable to delivered units is limited to the amount that is not contingent on the delivery of additional items or fulfillment of other performance conditions. Consequently, the arrangement consideration related to the research activities to be performed on behalf of Merck after the transfer of the technology was excluded from the allocation arrangement consideration because the consideration and performance are contingent upon Merck requesting performance of the services and these services are priced at an estimated fair value. The Company received and recorded non-refundable During the nine months September 30, 2019, the Company recorded $nil (2018: $nil) in research support payments from Merck, under the terms of the amended agreement. Licensing and Collaboration Agreement with Eli Lilly and Company (“Lilly”) On December 17, 2013, the Company entered into a Licensing and Collaboration Agreement with Lilly to develop novel bispecific antibody therapeutics using the Company’s proprietary Azymetric platform. The Company will apply its Azymetric platform in combination with Lilly’s proprietary targets to create novel bispecific antibodies which Lilly will have the right to develop and commercialize worldwide. Upon the execution of the agreement, the Company received a one-time, non-refundable The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Lilly, is a customer. The Company identified the following promised goods and services at the inception of the Lilly agreement: (1) the research license, (2) the commercial license, (3) the transfer of the Company’s platform technology (Azymetric), (4) the research services and technical assistance to be provided by the Company in connection with the transfer of intellectual property to Lilly, and (5) research activities to be performed on behalf of Lilly. The Company concluded that the licenses and platform technology together are distinct. Accordingly, the deliverables (1) through (4) were considered as a single performance obligation and the upfront payment of $1.0 million has been allocated to this performance obligation. The payment was recorded as deferred revenue and recognized into revenue on a straight-line basis from December 31, 2013 to June 30, 2014, the period over which the Company performed the procedures for transferring the Company’s know-how In order to evaluate the appropriate transaction price, the Company determined that the upfront amount constituted the entirety of the consideration to be included in the transaction price and to be allocated to the performance obligations based on the Company’s best estimate of their relative stand-alone selling prices. The Company estimated the best estimate of selling price of the licenses and technology platform based on comparable license and collaboration arrangements. The best estimate of selling price for the other deliverables was estimated using internal estimates of cost to perform the specific services plus a normal profit margin for providing the services. At execution, the transaction price included only the $1.0 million upfront consideration received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Lilly and therefore have also been excluded from the transaction price. The Company will re-evaluate The consideration otherwise allocable to delivered units is limited to the amount that is not contingent on the delivery of additional items or fulfillment of other performance conditions. Consequently, the arrangement consideration related to the research activities to be performed on behalf of Lilly after the transfer of the technology was excluded from the allocation arrangement consideration because the consideration and performance are contingent upon Lilly requesting performance of the services and these services are priced at an estimated fair value. On December 11, 2015, the Company recorded non-refundable non-refundable During the nine months September 30, 2019, the Company recorded $nil (2018: $nil) in research support revenue from Lilly. Lilly was a related party during 2018 but was not considered a related party as of December 31, 2018 and thereafter. Licensing and Collaboration Agreement with Lilly On October 22, 2014, the Company entered into a second Licensing and Collaboration Agreement with Lilly to develop novel bispecific antibody therapeutics using the Company’s proprietary Azymetric platform. This agreement did not alter or amend the initial agreement entered into on December 17, 2013. Under the terms of this agreement, the Company will apply its Azymetric platform in combination with Lilly’s proprietary targets to create novel bispecific antibodies which Lilly will develop and commercialize. In 2017 Lilly nominated a bispecific antibody from this agreement for preclinical development and discontinued the research of two other bispecific antibodies due to strategic portfolio realignment in those particular disease areas. Each of the two agreements with Lilly were negotiated independently and the deliverables covered by the respective contracts are unrelated to one another as they cover different product candidates. Accordingly, the second Licensing and Collaboration Agreement with Lilly has been accounted for as a new arrangement. The Company is eligible to receive potential milestone payments totaling up to $125.0 million, comprised of up to $2.0 million for research success milestone, up to $8.0 million for IND submission milestones, up to $20.0 million for development milestones and up to $95.0 million for commercial milestones. In addition, the Company is eligible to receive tiered royalty payments on the sale of products. Lilly will have exclusive worldwide commercialization rights to products derived from the collaboration. No license, research, development and commercial milestones or royalty payments have been received to date. The Company determined that other than the research milestone, the events and conditions resulting in payments for development and commercial milestones solely depend on Lilly’s performance. The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Lilly, is a customer. At execution, there was no upfront fee received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Lilly and therefore have also been excluded from the transaction price. The Company will re-evaluate On December 1, 2016, the Company recorded a non-refundable non-refundable No other research, development or commercial milestone payments or royalties have been received to date. Licensing and Collaboration Agreement with Celgene Corporation & Celgene Alpine Investment Co. LLC (“Celgene”) On December 23, 2014, the Company entered into an agreement with Celgene to develop novel bispecific antibody therapeutics using the Company’s proprietary Azymetric platform. The Company will apply its Azymetric platform in combination with Celgene’s proprietary targets to create novel bispecific antibodies for which Celgene has an option to develop and commercialize a certain number of products (“Commercial License Option”). Upon the execution of the Agreement, the Company received a one-time, non-refundable The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Celgene, is a customer. The Company identified the following promised goods and services at the inception of the Celgene agreement: (1) the non-exclusive know-how, six-month know-how In order to evaluate the appropriate transaction price, the Company determined that the upfront amount constituted the entirety of the consideration to be included in the transaction price and to be allocated to the performance obligations based on the Company’s best estimate of their relative stand-alone selling prices. The Company estimated the best estimate of selling price of the licenses and technology platform based on comparable license and collaboration arrangements. At execution, the transaction price included only the $8.0 million upfront consideration received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Celgene and therefore have also been excluded from the transaction price. The Company will re-evaluate On April 22, 2018, Celgene exercised its right to increase the number of potential products it can develop and commercialize from eight ten No development or commercial milestone payments or royalties have been received to date. Collaboration and License Agreement with GlaxoSmithKline Intellectual Property Development Ltd. (“GSK”) On December 1, 2015, the Company entered into a Collaboration and License Agreement with GSK for the research, development, and commercialization of novel Fc-engineered At the conclusion of the research collaboration, both GSK and the Company will have the right to develop and commercialize monoclonal and bispecific antibody candidates that incorporate the Company’s optimized immune-modulating Fc domains. Under the terms of the agreement, GSK will have the right to develop a minimum of four products across multiple disease areas, and the Company will be eligible to receive research, development, and commercial milestones of up to $110.0 million for each product. In addition, the Company is eligible to receive tiered sales royalties. Under the terms of the agreement, each party is liable for their own internal and external research costs incurred in the project. Furthermore, the Company will have the right to develop up to four products with the intellectual property arising from the collaboration without any royalty or milestone payment to GSK. The Company determined that, the events and conditions resulting in payments for research, development and commercial milestones solely depend on GSK’s performance. The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, GSK, is a customer. At execution, there was no upfront fee received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to GSK and therefore have also been excluded from the transaction price. The Company will re-evaluate No development or commercial milestone payments or royalties have been received to date. Platform Technology Transfer and License Agreement with GSK On April 21, 2016, the Company entered into a Platform Technology Transfer and License Agreement with GSK for the research, development, and commercialization of novel bispecific antibodies enabled using the Company’s Azymetric platform. Each of the two agreements with GSK were negotiated independently and the deliverables covered by the respective contracts utilize different therapeutic platforms and are unrelated to one another. Accordingly, the Platform Technology and License Agreement with GSK has been accounted for as a new arrangement. In May 2019, this agreement was expanded to provide GSK access to Zymeworks’ unique heavy-light chain pairing technology under the Azymetric platform. This may include bispecific antibodies incorporating new engineered Fc regions generated under the 2015 GSK agreement. Upon execution of the agreement, the Company received a technology access fee of $6.0 million on May 3, 2016. The Company is also eligible to receive up to $37.5 million in research milestone payments; up to $183.5 million in development milestone payments; and up to $867.0 million in commercial sales milestone payments. In addition, the Company is entitled to receive tiered royalties on potential sales. The Company determined that, the events and conditions resulting in payments for research, development and commercial milestones solely depend on GSK’s performance. The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, GSK, is a customer. The Company identified the following promised goods and services at the inception of the GSK agreement: (1) the non-exclusive know-how, know-how In order to evaluate the appropriate transaction price, the Company determined that the upfront amount constituted the entirety of the consideration to be included in the transaction price and to be allocated to the performance obligations based on the Company’s best estimate of their relative stand-alone selling prices. The Company estimated the best estimate of selling price of the licenses and technology platform based on comparable license and collaboration arrangements. The Company concluded that the best estimate of selling price for the obligation to deliver future technology improvements and updates was a nominal amount, as the Company has no intention of performing and has made no commitment to perform or provide additional update work on the applicable technology platform. Accordingly, no arrangement consideration was allocated to this deliverable. At execution, the transaction price included only the $6.0 million upfront consideration received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to GSK and therefore have also been excluded from the transaction price. The Company will re-evaluate No research, development or commercial milestone payments or royalties have been received to date. Collaboration and Cross License Agreement with Daiichi Sankyo, Co., Ltd. (“Daiichi Sankyo”) On September 26, 2016, the Company entered into a Collaboration and Cross License Agreement with Daiichi Sankyo for the research, development, and commercialization of novel bispecific antibodies enabled using the Company’s Azymetric and EFECT platforms. Additionally, the Company will license immuno-oncology antibodies from Daiichi Sankyo, with the right to research, develop and commercialize multiple products globally in exchange for royalties on product sales. Under the agreement, Daiichi Sankyo will have the option to develop and commercialize a single bispecific immuno-oncology therapeutic. Upon execution of the agreement, the Company received a technology access fee of $2.0 million. The Company is also eligible to receive up to $67.9 million in research and development milestone payments and commercial license option; and up to $80.0 million in commercial sales milestone payments. In addition, the Company is eligible to receive tiered royalties on potential product sales. The Company determined that other than a research milestone for $1.0 million, the events and conditions resulting in payments for research, development and commercial milestones solely depend on Daiichi Sankyo’s performance. In April 2019, the Company recognized $3.5 million revenue on Daiichi Sankyo’s exercise of its option to obtain a commercial license with respect to its first Azymetric lead product candidate. The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Daiichi Sankyo, is a customer. The Company identified the following promised goods and services at the inception of the Daiichi Sankyo agreement: (1) the research license, (2) the transfer of the Company’s platform technologies (Azymetric and EFECT) and relevant know-how, In order to evaluate the appropriate transaction price, the Company determined that the upfront amount constituted the entirety of the consideration to be included in the transaction price and to be allocated to the performance obligations based on the Company’s best estimate of their relative stand-alone selling prices. The Company estimated the best estimate of selling price of the licenses and technology platform based on comparable license and collaboration arrangements. The best estimate of selling price for the other deliverables was estimated using internal estimates of cost to perform the specific services plus a normal profit margin for providing the services. At execution, the transaction price included only the $2.0 million upfront consideration received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Daiichi Sankyo and therefore have also been excluded from the transaction price. The Company will re-evaluate The consideration otherwise allocable to delivered units is limited to the amount that is not contingent on the delivery of additional items or fulfillment of other performance conditions. Consequently, the arrangement consideration related to the research activities to be performed on behalf of Daiichi Sankyo after the transfer of the technology was excluded from the allocation arrangement consideration because the consideration and performance are contingent upon Daiichi Sankyo requesting performance of the services and these services are priced at an estimated fair value. On June 26, 2017, the Company recorded non-refundable During the nine months ended September 30, 2019, the Company recorded $nil in research support revenue from Daiichi Sankyo (2018: $nil). Second License Agreement with Daiichi Sankyo In May 2018, the Company entered into a second license agreement with Daiichi Sankyo to research, develop and commercialize two bispecific antibodies generated through the use of the Azymetric and EFECT platforms. Under the terms of the agreement, the Company granted Daiichi Sankyo a worldwide, royalty-bearing, antibody sequence pair-specific, exclusive license to research, develop and commercialize certain products. Under the agreement, Daiichi Sankyo will be solely responsible for the research, development, manufacturing and commercialization of the products. Upon execution of the agreement, the Company received a non-refundable product-by-product country-by-country The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Daiichi Sankyo, is a customer. The Company identified the following promised goods and services at the inception of the Daiichi agreement: (1) the research and commercial license, (2) the transfer of the Company’s platform technologies (Azymetric and EFECT) and relevant know-how. The Company concluded that the licenses and platform technologies together are distinct. Accordingly, the deliverables (1) and (2) were considered as a single performance obligation and the upfront fee of $18.0 million was allocated to this performance obligation and was recognized as revenue upon delivery of the licenses and transfer of the relevant technology. In order to evaluate the appropriate transaction price, the Company determined that the upfront amount constituted the entirety of the consideration to be included in the transaction price and to be allocated to the performance obligations based on the Company’s best estimate of their relative stand-alone selling prices. The Company estimated the best estimate of selling price of the licenses and technology platform based on comparable license and collaboration arrangements. At execution, the transaction price included only the $18.0 million upfront consideration received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Daiichi Sanyo and therefore have also been excluded from the transaction price. The Company will re-evaluate No development or commercial milestone payments or royalties have been received to date. Collaboration and License Agreement with Janssen Biotech, Inc. (“Janssen”) On November 13, 2017, the Company entered into a Collaboration and License Agreement with Janssen to research, develop and commercialize up to six bispecific antibodies generated through the use of the Azymetric and EFECT platforms. Under the terms of the agreement, the Company granted Janssen a worldwide, royalty-bearing, antibody sequence pair-specific exclusive license to research, develop and commercialize certain products. Janssen also has the option to develop two additional bispecific antibodies under this agreement subject to a future option payment. Under the agreement, Janssen will be solely responsible for the research, development, manufacturing and commercialization of the products. Upon execution of the agreement, the Company received a non-refundable mid-single product-by-product country-by-country The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Janssen, is a customer. The Company identified the following promised goods and services at the inception of the Janssen agreement: (1) the research and commercial license, (2) the transfer of the Company’s platform technologies (Azymetric and EFECT) and relevant know-how. In order to evaluate the appropriate transaction price, the Company determined that the upfront amount constituted the entirety of the consideration to be included in the transac

Leases

Leases	9 Months Ended
	Sep. 30, 2019
Text Block [Abstract]
Leases	9. Leases The Company leases office premises in Vancouver, British Columbia and Seattle, Washington that expire in August 2021 and February 2022, respectively. The Company has also entered into a lease for laboratory space in Vancouver, British Columbia that will expire in August 2021. The leases contain rent escalation clauses. The Company entered into a lease on January 25, 2019 in Vancouver to serve as the Company’s future head office. The commencement date of this lease will be no later than September 21, 2021, and has an initial term of ten years, with two five-year extension options. April 30, 2025 right-of-use The balance sheet classification of the Company’s lease liabilities was as follows: September 30, December 31, Operating lease liabilities: Current portion $ 912 $ — Long-term portion 5,843 — Total operating lease liabilities 6,755 $ — Finance lease liabilities: Current portion included in other current liabilities 9 15 Long-term portion included in other long-term liabilities 47 42 Total finance lease liabilities 56 57 Total lease liabilities $ 6,811 $ 57 Cash paid for amounts included in the measurement of operating lease liabilities for the nine months ended September 30, 2019 was $1.2 million and was included in net cash provided by operating activities in the consolidated statements of cash flows. As of September 30, 2019, the maturities of the Company’s operating lease liabilities were as follows: Operating Within 1 year $ 1,307 1 to 2 years 2,253 2 to 3 years 1,131 3 to 4 years 982 4 to 5 years 1,010 Thereafter 604 Total operating lease payments 7,287 Less: Imputed interest (532 ) Operating lease liabilities $ 6,755 As of September 30, 2019, the weighted average remaining lease term is 4.3 years and the discount rate used to determine the operating lease liability was 4.6% for leases in Canadian dollar and 2.9% for leases in U.S. dollar. During the three months ended September 30, 2019, the Company incurred total operating lease expenses of $698, which included lease expenses associated with fixed lease payments of $657, and variable payments associated with Common area maintenance and similar expenses of $41. The Company also leases office equipment under finance lease agreements. As of September 30, 2019, the maturities of the Company’s finance lease liabilities were as follows: Finance Within 1 year $ 27 1 to 2 years 22 2 to 3 years 6 3 to 4 years 4 4 to 5 years 2 Thereafter — Total finance lease payments 61 Less: Imputed interest (5 ) Finance lease liabilities $ 56

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Commitments The Company has entered into research collaboration agreements with strategic partners in the ordinary course of operations that may include contractual milestone payments related to the achievement of pre-specified any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements and the Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to indemnification obligations for any period presented. In August 2016, the Company entered into a license agreement with Innovative Targeting Solutions Inc., (“ITS”), to use ITS’ protein engineering technology for the development and commercialization of antibody and protein therapeutics. Pursuant to the agreement, the Company agreed to pay an aggregate of $12.0 million in annual licensing fees to ITS over a five-year period over useful lives . The Company may also be required to make payments to ITS upon the achievement of certain development and commercial milestones, as well as royalty payments on net sales. No liabilities have been recorded for any amounts payable as of September 30, 2019. In connection with the Kairos acquisition, the Company may be required to make future payments to CVI upon the direct achievement of certain development milestones for products incorporating certain Kairos intellectual property, as well as royalty payments on the net sales of such products. For out-licensed mid-single Contingencies From time to time, the Company may be subject to various legal proceedings and claims related to matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred .

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited financial statements and notes for the year ended December 31, 2018. These unaudited interim financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and nine months ended September 30, 2019 and 2018 are not necessarily indicative of results that can be expected for a full year. These unaudited interim financial statements follow the same significant accounting policies as those described in the notes to the audited financial statements of the Company for the year ended December 31, 2018, except for the new accounting guidance adopted during the period (note 3 ). Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. All amounts expressed in the interim condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for per share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” are to Canadian dollars.
Use of Estimates	Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. In preparing these interim condensed consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, some of which are those related to revenue recognition including estimated timing of completion of performance obligations required to meet revenue recognition criteria, Scientific Research and Experimental Development (“SR&ED”) Program, stock-based compensation, warrants, accrual of expenses, preclinical study accruals, valuation allowance for deferred taxes, other contingencies and valuation of assets acquired in a business combination. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.
Fair Value Measurements	Fair Value Measurements The Company measures certain financial instruments and other items at fair value. To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows: • Level 1 inputs are quoted market prices for identical instruments available in active markets. • Level 2 inputs are inputs other than Level 1 prices, such as prices for similar asset or liability that are observable either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets. • Level 3 inputs are unobservable inputs for the asset or liability and will reflect management’s assumptions about market assumptions that would be used to price the asset or liability. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s financial instruments consist of cash and cash equivalents, short-term investments, amounts receivable, accounts payable and accrued liabilities, finance and operating The carrying values of cash and cash equivalents, short-term investments, amounts receivable and accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments. As quoted prices for the liability classified stock options are not readily available, the Company has used a Black-Scholes pricing model to estimate fair value, which utilizes level 3 inputs as defined above. Other long-term liabilities for contingent consideration related to business acquisitions are recorded at fair value on the acquisition date and adjusted quarterly for changes in its fair value. Changes in the fair value of contingent consideration liabilities can result from changes in anticipated milestone payments and changes in assumed discount periods and rates. These inputs are unobservable in the market and therefore categorized as level 3 inputs as defined above. The following tables present information about the Company’s liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value: September 30, Level 1 Level 2 Level 3 Liabilities Liability classified stock options $ 22,846 $ — $ — $ 22,846 Liability for contingent consideration (note 10) 992 — — 992 Total $ 23,838 $ — $ — $ 23,838 December 31, Level 1 Level 2 Level 3 Liabilities Liability classified stock options $ 12,603 $ — $ — $ 12,603 Liability for contingent consideration (note 10) 707 707 Total $ 13,310 $ — $ — $ 13,310 The following table presents the changes in fair value of the liability classified stock options: Liability at Reclassification to Increase (decrease) in Exercise of Unrealized foreign Liability at end of Three months ended September 30, 2019 $ 20,127 $ — $ 3,687 $ (796 ) $ (172 ) $ Nine months ended September 30, 2019 $ 12,603 $ 119 $ 11,850 $ (2,009 ) $ 283 $ 22,846 The following table presents the changes in fair value of the Company’s liability for contingent consideration: Liability at Increase (decrease) in Liability at end Three months ended September 30, 2019 $ 992 $ — $ 992 Nine months ended September 30, 2019 $ 707 $ 285 $ 992
Net loss per share	Net loss per share Basic net loss per share attributable to common shareholders is computed by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to common shareholders is computed by adjusting net loss attributable to common shareholders to reallocate undistributed earnings based on the potential impact of dilutive securities, including stock options and warrants. Diluted net loss per share attributable to common shareholders is computed by dividing the diluted net loss attributable to common shareholders by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding instruments. ASC 260 “Earnings Per Share” requires an adjustment to the numerator for any income or loss related to ASC 815 liability classified warrants and stock options, if dilutive, if they are presumed to be share settled. The stock options outstanding were excluded from the calculation of diluted loss per share because their inclusion would have been anti-dilutive. Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Numerator: Net loss attributable to common shareholders: Basic $ (30,475 ) $ (18,751 ) $ (73,193 ) $ (45,829 ) Diluted $ (30,475 ) $ (18,751 ) $ (73,193 ) $ (45,829 ) Denominator: Weighted-average common shares outstanding: Basic (*) 43,445,379 31,959,206 36,143,113 28,119,872 Diluted 43,445,379 31,959,206 36,143,113 28,119,872 Net loss per common share—basic $ (0.70 ) $ (0.59 ) $ (2.03 ) $ (1.63 ) Net loss per common share—diluted $ (0.70 ) $ (0.59 ) $ (2.03 ) $ (1.63 ) (*): Weighted average number of common shares used in the basic earnings per share calculation for the three and nine months ended September 30, 2019 includes the pre-funded warrants issued in connection with the Company’s June 2019 offering as the warrants are exercisable at any time and for nominal cash consideration.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Schedule of Financial Liabilities Measured at Fair Value on a Recurring Basis	The following tables present information about the Company’s liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value: September 30, Level 1 Level 2 Level 3 Liabilities Liability classified stock options $ 22,846 $ — $ — $ 22,846 Liability for contingent consideration (note 10) 992 — — 992 Total $ 23,838 $ — $ — $ 23,838 December 31, Level 1 Level 2 Level 3 Liabilities Liability classified stock options $ 12,603 $ — $ — $ 12,603 Liability for contingent consideration (note 10) 707 707 Total $ 13,310 $ — $ — $ 13,310
Schedule of Changes in Fair Value of Liability Classified Stock Options	The following table presents the changes in fair value of the liability classified stock options: Liability at Reclassification to Increase (decrease) in Exercise of Unrealized foreign Liability at end of Three months ended September 30, 2019 $ 20,127 $ — $ 3,687 $ (796 ) $ (172 ) $ Nine months ended September 30, 2019 $ 12,603 $ 119 $ 11,850 $ (2,009 ) $ 283 $ 22,846
Summary of Changes in Fair Value of the Company's Liability for Contingent Consideration	The following table presents the changes in fair value of the Company’s liability for contingent consideration: Liability at Increase (decrease) in Liability at end Three months ended September 30, 2019 $ 992 $ — $ 992 Nine months ended September 30, 2019 $ 707 $ 285 $ 992
Summary of Calculation of Diluted Loss Per Share	The stock options outstanding were excluded from the calculation of diluted loss per share because their inclusion would have been anti-dilutive. Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Numerator: Net loss attributable to common shareholders: Basic $ (30,475 ) $ (18,751 ) $ (73,193 ) $ (45,829 ) Diluted $ (30,475 ) $ (18,751 ) $ (73,193 ) $ (45,829 ) Denominator: Weighted-average common shares outstanding: Basic (*) 43,445,379 31,959,206 36,143,113 28,119,872 Diluted 43,445,379 31,959,206 36,143,113 28,119,872 Net loss per common share—basic $ (0.70 ) $ (0.59 ) $ (2.03 ) $ (1.63 ) Net loss per common share—diluted $ (0.70 ) $ (0.59 ) $ (2.03 ) $ (1.63 ) (*): Weighted average number of common shares used in the basic earnings per share calculation for the three and nine months ended September 30, 2019 includes the pre-funded warrants issued in connection with the Company’s June 2019 offering as the warrants are exercisable at any time and for nominal cash consideration.

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Changes and Error Corrections [Abstract]
Schedule of Impact on Company's Balance Sheet Due to Adoption of Accounting Pronouncements	The impact of the adoption of Topic 842 on the accompanying Condensed Consolidated Balance Sheet as of January 1, 2019 was as follows: Operating lease right-of-use (1) $ — $ 3,222 $ 3,222 Total lease inducements (2) 333 (333 ) — Total operating lease liabilities (3) — 3,561 3,561 (1) Right-of-use Right-of-use (2) Included in current and long-term other liabilities (note 6) (3) Includes current and non-current The impact of the adoption of Topic 842 on the accompanying Condensed Consolidated Statements of Operations for three and nine months ended September 30, 2019 were as follows: As Effect of Balances Operating expenses for the three months ended September 30, 2019 $ 41,424 $ 158 $ 41,266 Operating expenses for the nine months ended September 30, 2019 $ 105,216 $ 408 $ 104,808

IPR&D and Goodwill (Tables)

IPR&D and Goodwill (Tables)	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Carrying Value of IPR&D, Net of Impairment	The following table summarizes the carrying value of IPR&D, net of impairment: Acquired IPR&D Net Balance at December 31, 2018 $ 20,700 $ (2,304 ) $ 18,396 Change during the period — (768 ) (768 ) Balance at September 30, 2019 $ 20,700 $ (3,072 ) $ 17,628

Liabilities (Tables)

Liabilities (Tables)	9 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following: September 30, December 31, Trade payables $ 8,040 $ 2,599 Accrued research expenses 13,589 6,633 Employee compensation and vacation accruals 3,430 2,926 Accrued legal and professional fees 1,036 556 Other 827 689 Total $ 26,922 $ 13,403
Schedule of Other Current Liabilities	Other current liabilities consisted of the following: September 30, December 31, Current income tax liability $ — $ 299 Current portion of lease inducements — 136 Current portion of finance lease liability (note 9) 9 15 Total $ 9 $ 450
Schedule of Other Long-term Liabilities	Other long-term liabilities consisted of the following: September 30, December 31, Liability for contingent consideration (note 10) $ 992 $ 707 Lease inducements — 197 Finance lease liability (note 9) 47 42 Total $ 1,039 $ 946

Redeemable Convertible Class _2

Redeemable Convertible Class A Preferred Shares, and Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Summary of Stock Options Granted	Number Weighted- Weighted- Weighted- Aggregate Aggregate Outstanding, December 31, 2018 2,445,990 14.66 10.74 6.99 14,421 10,571 Granted 322,800 21.34 15.91 Exercised (241,906 ) 10.60 7.97 Forfeited (37,906 ) 17.45 13.18 Outstanding, September 30, 2019 2,488,978 15.88 11.99 6.86 42,215 31,883
Schedule of Stock-based compensation expense	Stock-based compensation expense for equity classified instruments, as well as the financial statement impact of the periodic revaluation of liability classified equity instruments (note 2), is recorded in research and development expenses, general and administration expenses and finance expense (income) as follows:​​​​​​​ Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Research and development expenses: Stock-based compensation for equity classified instruments $ 1,690 $ 691 $ 4,324 $ 1,724 Change in fair value of liability classified equity instruments 888 496 2,856 1,966 $ 2,578 $ 1,187 $ 7,180 $ 3,690 General and administrative expenses: Stock-based compensation for equity classified instruments $ 1,721 $ 1,093 $ 4,791 $ 2,758 Change in fair value of liability classified equity instruments 2,781 1,304 8,908 5,342 $ 4,502 $ 2,397 $ 13,699 $ 8,100 Finance expenses: Stock-based compensation for equity classified instruments $ — $ — $ — $ 1 Change in fair value of liability classified equity instruments 18 39 86 152 $ 18 $ 39 $ 86 $ 153
Schedule of Estimated Fair Value of Stock Options Assumptions	The estimated fair value of stock options granted in U.S. dollars under the New Plan was determined using the Black-Scholes option pricing model with the following weighted-average assumptions: Nine Months Ended September 30, 2019 2018 Dividend yield 0% 0% Expected volatility 72.91% 66.0% Risk-free interest rate 2.36% 2.64% Expected average life of options 6.02 years 5.87 years
U.S Dollar Under the New Option Stock Plan [Member]
Summary of Stock Options Granted	Number Weighted- Weighted- Aggregate Outstanding, December 31, 2018 1,539,778 11.67 9.02 4,876 Granted 1,210,050 17.07 Exercised (59,218 ) 12.94 Forfeited (30,261 ) 15.52 Outstanding, September 30, 2019 2,660,349 14.05 8.79 28,659
Employee Stock Option [Member]
Schedule of Estimated Fair Value of Stock Options Assumptions	The estimated fair value of stock options granted in Canadian dollars under the Original Plan and the New Plan was determined using the Black-Scholes option pricing model with the following weighted-average assumptions: Nine Months Ended September 30, 2019 2018 Dividend yield 0% 0% Expected volatility 73.74% 66.0% Risk-free interest rate 1.46% 2.17% Expected average life of options 6.05 years 5.91 years
Liability Classified Stock Options [Member]
Schedule of Estimated Fair Value of Stock Options Assumptions	The weighted-average Black-Scholes option pricing assumptions for liability classified stock options are as follows: September 30, September 30, Dividend yield 0% 0% Expected volatility 72.8% 66.5% Risk-free interest rate 1.47% 1.55% Expected average option term 3.56 years 5.89 years Number of liability classified stock options outstanding 1,327,334 1,441,163

Research, Collaboration and L_2

Research, Collaboration and Licensing Agreements (Tables)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Revenue Recognized from Strategic Partnerships	The following table presents summarized revenue recognized from the Company’s strategic partnerships. Three Months Ended Nine Months Ended 2019 2018 2019 2018 BeiGene: Recognition of upfront fee $ — $ — $ 3,530 $ — Lilly: Milestone revenue — 2,000 8,000 2,000 Daiichi Sankyo: Upfront technology access fee — — — 18,000 Commercial license option fee — — 3,500 — LEO: Research support payments 336 — 1,108 — Celgene: Option exercise fee 7,500 — 7,500 4,000 Merck: Milestone revenue — — 2,000 — Iconic: Milestone revenue — — 1,000 — Research support and supplies payments 24 — 1,029 — Other: Research support payments — 54 — 94 $ 7,860 $ 2,054 $ 27,667 $ 24,094

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Text Block [Abstract]
Schedule of Balance Sheet Classification of Lease Liabilities	The balance sheet classification of the Company’s lease liabilities was as follows: September 30, December 31, Operating lease liabilities: Current portion $ 912 $ — Long-term portion 5,843 — Total operating lease liabilities 6,755 $ — Finance lease liabilities: Current portion included in other current liabilities 9 15 Long-term portion included in other long-term liabilities 47 42 Total finance lease liabilities 56 57 Total lease liabilities $ 6,811 $ 57
Schedule of Maturities of Operating Lease Liabilities	As of September 30, 2019, the maturities of the Company’s operating lease liabilities were as follows: Operating Within 1 year $ 1,307 1 to 2 years 2,253 2 to 3 years 1,131 3 to 4 years 982 4 to 5 years 1,010 Thereafter 604 Total operating lease payments 7,287 Less: Imputed interest (532 ) Operating lease liabilities $ 6,755
Schedule of Maturities of Finance Lease Liabilities	The Company also leases office equipment under finance lease agreements. As of September 30, 2019, the maturities of the Company’s finance lease liabilities were as follows: Finance Within 1 year $ 27 1 to 2 years 22 2 to 3 years 6 3 to 4 years 4 4 to 5 years 2 Thereafter — Total finance lease payments 61 Less: Imputed interest (5 ) Finance lease liabilities $ 56

Nature of Operations - Addition

Nature of Operations - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Jun. 24, 2019	Sep. 30, 2019	Jun. 20, 2019	Jan. 31, 2019
Date of incorporation		Sep. 8, 2003
Offering [Member]
Warrants issued price per pre funded warrant	$ 17.9999		$ 17.9999
Final prospectus supplement, shares price | $ / shares	$ 18		$ 18
Number of shares issued	7,013,892
Net proceeds from issuance | $	$ 188
Over-Allotment Option [Member]
Pre funded warrants issued in lieu of common shares to underwriters	4,166,690
Number of shares issued to underwriters	1,458,336
Maximum [Member]
Aggregate offering price | $				$ 250

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Financial Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Liabilities
Financial liabilities measured at fair value	$ 23,838	$ 13,310
Liability Classified Stock Options [Member]
Liabilities
Financial liabilities measured at fair value	22,846	12,603
Liability for Contingent Consideration [Member]
Liabilities
Financial liabilities measured at fair value	992	707
Level 3 [Member]
Liabilities
Financial liabilities measured at fair value	23,838	13,310
Level 3 [Member] | Liability Classified Stock Options [Member]
Liabilities
Financial liabilities measured at fair value	22,846	12,603
Level 3 [Member] | Liability for Contingent Consideration [Member]
Liabilities
Financial liabilities measured at fair value	$ 992	$ 707

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Liability Classified Stock Options (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liability at beginning of the period		$ 12,603
Liability at end of the period	$ 22,846	22,846
Liability Classified Stock Options [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liability at beginning of the period	20,127	12,603
Reclassification to liabilities from equity		119
Increase (decrease) in fair value of liability classified stock options	3,687	11,850
Exercise of options	(796)	(2,009)
Unrealized foreign currency loss (gain)	(172)	283
Liability at end of the period	$ 22,846	$ 22,846

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Changes in Fair Value of the Company's Liability for Contingent Consideration (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Liability at the beginning of the period	$ 992	$ 707
Increase (decrease) in fair value of liability for contingent consideration		285	$ 53
Liability at end of the period	$ 992	$ 992

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Calculation of Diluted Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net loss attributable to common shareholders:
Basic		$ (30,475)	$ (18,751)	$ (73,193)	$ (45,829)
Diluted		$ (30,475)	$ (18,751)	$ (73,193)	$ (45,829)
Weighted-average common shares outstanding:
Basic	[1]	43,445,379	31,959,206	36,143,113	28,119,872
Diluted		43,445,379	31,959,206	36,143,113	28,119,872
Net loss per common share—basic		$ (0.70)	$ (0.59)	$ (2.03)	$ (1.63)
Net loss per common share—diluted		$ (0.70)	$ (0.59)	$ (2.03)	$ (1.63)
[1]	Weighted average number of common shares used in the basic earnings per share calculation for the three and nine months ended September 30, 2019 includes the pre-funded warrants issued in connection with the Company’s June 2019 offering as the warrants are exercisable at any time and for nominal cash consideration.

Recent Accounting Pronounceme_3

Recent Accounting Pronouncement - Impact of the Adoption of Topic 842 On Balance Sheet (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating lease right-of-use assets	$ 5,443	$ 3,222
Total lease inducements			$ 333
Total operating lease liabilities	$ 6,755	3,561
Adjustments Due To The Adoption Of Topic 842 [Member]
Operating lease right-of-use assets		3,222
Total lease inducements		(333)
Total operating lease liabilities		$ 3,561

Recent Accounting Pronounceme_4

Recent Accounting Pronouncements - The impact of the Adoption of Topic 842 on the Accompanying Condensed Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Operating expenses	$ 41,424	$ 21,642	$ 105,216	$ 65,809
Effect Of Adoption Of Topic 842 [Member]
Operating expenses	158		408
Balances Without Adoption Of Topic 842 [Member]
Operating expenses	$ 41,266		$ 104,808

Short-Term Investments - Additi

Short-Term Investments - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2019
Short-Term Investments [Line Items]
Short-term investments maturity term	12 months
Description on short-term investments maturity	The Company may redeem GIC investments 30 days after deposit without penalty.
Minimum [Member]
Short-Term Investments [Line Items]
Short-term investments interest rate	2.00%
Maximum [Member]
Short-Term Investments [Line Items]
Short-term investments interest rate	3.00%

Intangible Assets and Goodwill

Intangible Assets and Goodwill - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Acquired Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 768
Goodwill impairment loss	0
IPR&D [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets	768
Deferred tax assets	207
Deferred tax liabilities	$ (207)

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Summary of Carrying Value of IPR&D, Net of Impairment (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Acquired Indefinite-lived Intangible Assets [Line Items]
Beginning balance	$ 18,396
Ending balance	17,628
IPR&D [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Acquired IPR&D, beginning balance	20,700
Acquired IPR&D, Change during the period	0
Acquired IPR&D, ending balance	20,700
Beginning balance	(2,304)
Change during the period	(768)
Ending balance	(3,072)
Beginning balance	18,396
Change during the period	(768)
Ending balance	$ 17,628

Liabilities - Schedule of Accou

Liabilities - Schedule of Accounts Payable and Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accounts Payable and Accrued Liabilities, Current [Abstract]
Trade payables	$ 8,040	$ 2,599
Accrued research expenses	13,589	6,633
Employee compensation and vacation accruals	3,430	2,926
Accrued legal and professional fees	1,036	556
Other	827	689
Total	$ 26,922	$ 13,403

Liabilities - Schedule of Other

Liabilities - Schedule of Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Other Liabilities, Current [Abstract]
Current income tax liability		$ 299
Current portion of lease inducements		136
Current portion of finance lease liability (note 9)	$ 9	15
Total	$ 9	$ 450

Liabilities - Schedule of Oth_2

Liabilities - Schedule of Other Long-term Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Other Liabilities, Noncurrent [Abstract]
Liability for contingent consideration (note 10)	$ 992	$ 707
Lease inducements		197
Finance lease liability (note 9)	47	42
Total	$ 1,039	$ 946

Redeemable Convertible Class _3

Redeemable Convertible Class A Preferred Shares, and Shareholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Thousands, $ in Thousands	Jun. 24, 2019$ / sharesshares	Jun. 07, 2018	Jul. 14, 2006	Sep. 30, 2019USD ($)shares	Sep. 30, 2019CAD ($)shares	Dec. 31, 2028	Jun. 20, 2019$ / shares	Dec. 31, 2018shares	Dec. 21, 2015shares
Temporary Equity [Line Items]
Redeemable convertible preferred shares, authorized									6,413,265
Preferred stock, shares issued				0				0
Preferred stock, shares outstanding				0				0
Shares granted with respect to maximum fixed amount equal, percentage			20.00%
Options granted under original plan exercisable period				10 years	10 years
Shares available for issuance under the Original Plan vesting period			4 years
Proceeds from stock options exercised				$ 2,686	$ 3,267
Unamortized compensation expense related to unvested options				$ 14,276	$ 18,905
Remaining unamortized compensation expense, weighted-average period				1 year 8 months 26 days	1 year 8 months 26 days
Total amount contributed by ESPP participants | $				$ 223
Warrant exercise price | $ / shares	$ 0.0001
Offering [Member]
Temporary Equity [Line Items]
Warrants issued price per pre funded warrant | $ / shares	17.9999						$ 17.9999
Final prospectus supplement, shares price | $ / shares | $ / shares	$ 18						$ 18
Number of shares issued	7,013,892
Over-Allotment Option [Member]
Temporary Equity [Line Items]
Pre funded warrants issued in lieu of common shares to underwriters	4,166,690
Minimum [Member]
Temporary Equity [Line Items]
Stock options expiration date				Sep. 30, 2019	Sep. 30, 2019
Maximum [Member]
Temporary Equity [Line Items]
Stock options expiration date				Sep. 16, 2029	Sep. 16, 2029
U.S Dollar Under the New Option Stock Plan [Member]
Temporary Equity [Line Items]
Shares granted with respect to maximum fixed amount equal, percentage		20.00%
Maximum number of common shares reserved for issuance				5,686,097
Shares issuable upon exercise of stock options								3,985,768
Maximum number of common shares reserved for issuance increase in percentage						4.00%
Employees Stock Purchase Plan [Member]
Temporary Equity [Line Items]
Shares granted with respect to maximum fixed amount equal, percentage				1.00%	1.00%
Percentage of discounted purchase price of average market price				85.00%	85.00%
Share-based compensation arrangement by share-based payment award, plan modification, description and terms				On June 7, 2018, certain amendments to the ESPP were approved by shareholders. Prior to these amendments, the ESPP allowed eligible employees to acquire common shares at a discounted purchase price of 85% of the market value of the Company’s common shares on the purchase date. The ESPP, as amended, allows eligible employees to acquire common shares at a discounted purchase price of the lesser of (i) 85% of the market price of a common share on the first day of the applicable purchase period and (ii) 85% of the market price of a common share on the purchase date.	On June 7, 2018, certain amendments to the ESPP were approved by shareholders. Prior to these amendments, the ESPP allowed eligible employees to acquire common shares at a discounted purchase price of 85% of the market value of the Company’s common shares on the purchase date. The ESPP, as amended, allows eligible employees to acquire common shares at a discounted purchase price of the lesser of (i) 85% of the market price of a common share on the first day of the applicable purchase period and (ii) 85% of the market price of a common share on the purchase date.
Maximum eligible employees contribution under ESPP				15.00%
Purchase of shares under ESPP, maximum limit for each employee | $				$ 25
Additional common shares authorized for issuance				419,000	419,000
Compensation charge | $				$ 232
Employees Stock Purchase Plan [Member] | Prior To Amendment [Member]
Temporary Equity [Line Items]
Percentage of discounted purchase price of average market price				85.00%	85.00%
Employees Stock Purchase Plan [Member] | After Amendment [Member]
Temporary Equity [Line Items]
Percentage of discounted purchase price of average market price				85.00%	85.00%
Employees Stock Purchase Plan [Member] | Maximum [Member]
Temporary Equity [Line Items]
Number of common shares reserved for issuance				272,350
Director [Member]
Temporary Equity [Line Items]
Shares available for issuance under the Original Plan vesting period			3 years

Redeemable Convertible Class _4

Redeemable Convertible Class A Preferred Shares, and Shareholders' Equity - Summary of Stock Options Granted (Detail) $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Sep. 30, 2019CAD ($)	Dec. 31, 2018CAD ($)
Canadian Dollar Under the New Option Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, Beginning balance	2,445,990	2,445,990
Number of Options, Granted	322,800	322,800
Number of Options, Exercised	(241,906)	(241,906)
Number of Options, Forfeited	(37,906)	(37,906)
Number of Options Outstanding, Ending balance	2,488,978	2,488,978	2,445,990	2,445,990
Weighted-Average Exercise Price, Outstanding, Beginning balance | (per share)	$ 10.74	$ 14.66
Weighted-Average Exercise Price, Granted | (per share)	15.91	21.34
Weighted-Average Exercise Price, Exercised | (per share)	7.97	10.60
Weighted-Average Exercise Price, Forfeited | (per share)	13.18	17.45
Weighted-Average Exercise Price, Outstanding, Ending balance | (per share)	$ 11.99	$ 15.88	$ 10.74	$ 14.66
Weighted-Average Contractual Term, Outstanding	6 years 10 months 9 days	6 years 10 months 9 days	6 years 11 months 26 days	6 years 11 months 26 days
Aggregate intrinsic value Outstanding	$ 31,883	$ 31,883	$ 10,571	$ 10,571	$ 42,215	$ 14,421
U.S Dollar Under the New Option Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, Beginning balance	1,539,778	1,539,778
Number of Options, Granted	1,210,050	1,210,050
Number of Options, Exercised	(59,218)	(59,218)
Number of Options, Forfeited	(30,261)	(30,261)
Number of Options Outstanding, Ending balance	2,660,349	2,660,349	1,539,778	1,539,778
Weighted-Average Exercise Price, Outstanding, Beginning balance | $ / shares	$ 11.67
Weighted-Average Exercise Price, Granted | $ / shares	17.07
Weighted-Average Exercise Price, Exercised | $ / shares	12.94
Weighted-Average Exercise Price, Forfeited | $ / shares	15.52
Weighted-Average Exercise Price, Outstanding, Ending balance | $ / shares	$ 14.05		$ 11.67
Weighted-Average Contractual Term, Outstanding	8 years 9 months 14 days	8 years 9 months 14 days	9 years 7 days	9 years 7 days
Aggregate intrinsic value Outstanding | $	$ 28,659	$ 28,659	$ 4,876	$ 4,876

Redeemable Convertible Class _5

Redeemable Convertible Class A Preferred Shares, and Shareholders' Equity - Schedule of Stock-based Compensation Expense for Equity Classified Instruments (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Research and development expenses	$ 29,251	$ 14,195	$ 70,511	$ 42,648
General and administrative expenses	12,173	7,447	33,937	23,161
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation for equity classified instruments	1,690	691	4,324	1,724
Change in fair value of liability classified equity instruments	888	496	2,856	1,966
Research and development expenses	2,578	1,187	7,180	3,690
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation for equity classified instruments	1,721	1,093	4,791	2,758
Change in fair value of liability classified equity instruments	2,781	1,304	8,908	5,342
General and administrative expenses	4,502	2,397	13,699	8,100
Finance Expense (Income) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation for equity classified instruments				1
Change in fair value of liability classified equity instruments	18	39	86	152
Finance expenses	$ 18	$ 39	$ 86	$ 153

Redeemable Convertible Class _6

Redeemable Convertible Class A Preferred Shares, and Shareholders' Equity - Schedule of Estimated Fair Value of Stock Options Assumptions (Detail) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Expected volatility	73.74%	66.00%
Risk-free interest rate	1.46%	2.17%
Expected average life of options	6 years 18 days	5 years 10 months 27 days
Liability Classified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Expected volatility	72.80%	66.50%
Risk-free interest rate	1.47%	1.55%
Expected average life of options	3 years 6 months 21 days	5 years 10 months 20 days
Number of options outstanding	1,327,334	1,441,163
U.S Dollar Under the New Option Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Expected volatility	72.91%	66.00%
Risk-free interest rate	2.36%	2.64%
Expected average life of options	6 years 7 days	5 years 10 months 13 days
Number of options outstanding	2,660,349		1,539,778

Research, Collaboration and L_3

Research, Collaboration and Licensing Agreements - Schedule Of Collaborative Arrangements and Noncollaborative Arrangement Transactions (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	$ 7,860,000	$ 2,054,000	$ 27,667,000	$ 24,094,000
Option Exercise Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	7,500,000		7,500,000	4,000,000
Bei Gene [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized			3,530,000
Eli Lilly and Company [Member] | Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized		2,000,000	8,000,000	2,000,000
Daiichi Sankyo, Co., Ltd [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized				18,000,000
Daiichi Sankyo, Co., Ltd [Member] | Commercial License Option Exercise [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized			3,500,000
LEO Pharma [Member] | Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	336,000		1,108,000
Merck Sharp and Dohme Research Ltd. [Member] | Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized			2,000,000
Merck Sharp and Dohme Research Ltd. [Member] | Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized			0	0
Iconic Therapeutics Inc [Member] | Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized			1,000,000
Iconic Therapeutics Inc [Member] | Research Support And Supplies Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	$ 24,000		$ 1,029,000
Other [Member] | Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized		$ 54,000		$ 94,000

Research, Collaboration and L_4

Research, Collaboration and Licensing Agreements - Additional Information - Strategic Partnership Revenue (Detail) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract assets	$ 0	$ 0
Bei Gene [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue	$ 32,941,000	$ 36,471,000

Research, Collaboration and L_5

Research, Collaboration and Licensing Agreements - Additional Information - Merck (Detail) - USD ($)	May 28, 2019	Dec. 03, 2014	Apr. 22, 2013	Sep. 20, 2012	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2012	Aug. 22, 2011
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					$ 7,860,000	$ 2,054,000	$ 27,667,000	$ 24,094,000
Merck Sharp & Dohme Research Ltd. [Member] | Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue							0	$ 0
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone removed from total milestones		$ 2,000,000
Remaining performance obligation					$ 0		0
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 2,000,000		$ 1,500,000	$ 2,000,000
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Investigational New Drug [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue							0
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue							0
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue							0
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue							$ 0
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		3,500,000
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		190,750,000
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Investigational New Drug [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		6,000,000
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		66,000,000
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 114,000,000
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities										$ 1,250,000
Performance obligation recognized									$ 1,250,000

Research, Collaboration and L_6

Research, Collaboration and Licensing Agreements - Additional Information - Lilly (Detail) - USD ($)	Aug. 31, 2018	Dec. 11, 2015	Dec. 17, 2013	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2014	Sep. 30, 2019	Sep. 30, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				$ 7,860,000	$ 2,054,000				$ 27,667,000	$ 24,094,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project One [Member] | Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 2,000,000	$ 1,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project One [Member] | Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue						$ 0	$ 0
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project One [Member] | Eligible to Receive [Member] | Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 1,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project One [Member] | Eligible to Receive [Member] | Investigational New Drug [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			2,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project One [Member] | Eligible to Receive [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			8,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project One [Member] | Eligible to Receive [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			40,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project One [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities			$ 1,000,000
Performance obligation recognized								$ 1,000,000

Research, Collaboration and L_7

Research, Collaboration and Licensing Agreements - Additional Information - Lilly Two (Detail) - USD ($)	Jan. 16, 2019	Dec. 01, 2016	Oct. 22, 2014	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				$ 7,860,000	$ 2,054,000	$ 27,667,000	$ 24,094,000
Eli Lilly and Company [Member] | Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					$ 2,000,000	8,000,000	$ 2,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project Two [Member] | Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 2,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project Two [Member] | Investigational New Drug [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue						0
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project Two [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue						0
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project Two [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue						$ 0
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project Two [Member] | Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 8,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project Two [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities			$ 0
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project Two [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			125,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project Two [Member] | Eligible to Receive [Member] | Maximum [Member] | Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			2,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project Two [Member] | Eligible to Receive [Member] | Maximum [Member] | Investigational New Drug [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			8,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project Two [Member] | Eligible to Receive [Member] | Maximum [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			20,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project Two [Member] | Eligible to Receive [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 95,000,000

Research, Collaboration and L_8

Research, Collaboration and Licensing Agreements - Additional Information - Celgene (Detail)	Apr. 22, 2018USD ($)Product	Apr. 21, 2018Product	Dec. 23, 2014USD ($)	Jul. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Jun. 30, 2015USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					$ 7,860,000	$ 2,054,000		$ 27,667,000	$ 24,094,000
Option Exercise Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					$ 7,500,000			7,500,000	$ 4,000,000
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of potential products to developed and commercialized | Product	10	8
Extended research program term	24 months
Collaborative agreement expansion fee	$ 4,000,000
Extended research program maturity period	2020-04
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue								0
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue								0
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue								$ 0
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment	$ 164,000,000
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | License Option [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 7,500,000
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			164,000,000
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | Maximum [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			101,500,000
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			55,000,000
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities			$ 8,000,000
Performance obligation recognized							$ 8,000,000
Celgene [Member] | Cross License Agreement [Member] | Collaborative Arrangement [Member] | Option Exercise Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				$ 7,500,000

Research, Collaboration and L_9

Research, Collaboration and Licensing Agreements - Additional Information - GSK (Detail) - USD ($)	Dec. 01, 2015	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 7,860,000	$ 2,054,000	$ 27,667,000	$ 24,094,000
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				$ 0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities	$ 0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 110,000,000

Research, Collaboration and _10

Research, Collaboration and Licensing Agreements - Additional Information - GSK Two (Detail) - USD ($)	May 03, 2016	Apr. 21, 2016	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 7,860,000	$ 2,054,000	$ 27,667,000	$ 24,094,000
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | Platform Technology Transfer and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities	$ 6,000,000
Performance obligation recognized	$ 6,000,000
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | Platform Technology Transfer and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | Platform Technology Transfer and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | Platform Technology Transfer and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Commercial Sales Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | Platform Technology Transfer and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					$ 0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | Platform Technology Transfer and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 37,500,000
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | Platform Technology Transfer and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		183,500,000
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | Platform Technology Transfer and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Commercial Sales Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 867,000,000

Research, Collaboration and _11

Research, Collaboration and Licensing Agreements - Additional Information - Daiichi Sankyo (Detail) - USD ($)	Jun. 26, 2017	Sep. 26, 2016	Apr. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				$ 7,860,000	$ 2,054,000	$ 27,667,000	$ 24,094,000
Daiichi Sankyo, Co., Ltd [Member] | Commercial License Option Exercise [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue						3,500,000
Daiichi Sankyo, Co., Ltd [Member] | Cross License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment		$ 1,000,000
Daiichi Sankyo, Co., Ltd [Member] | Cross License Agreement [Member] | Collaborative Arrangement [Member] | Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities		2,000,000
Performance obligation recognized		2,000,000
Daiichi Sankyo, Co., Ltd [Member] | Cross License Agreement [Member] | Collaborative Arrangement [Member] | Research, Development, Commercial License Option Milestone [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		67,900,000
Daiichi Sankyo, Co., Ltd [Member] | Cross License Agreement [Member] | Collaborative Arrangement [Member] | Commercial Milestones [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 80,000,000
Daiichi Sankyo, Co., Ltd [Member] | Cross License Agreement [Member] | Collaborative Arrangement [Member] | Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 1,000,000
Daiichi Sankyo, Co., Ltd [Member] | Cross License Agreement [Member] | Collaborative Arrangement [Member] | Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research support revenue						$ 0	$ 0
Daiichi Sankyo, Co., Ltd [Member] | Cross License Agreement [Member] | Collaborative Arrangement [Member] | Commercial License Option Exercise [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 3,500,000

Research, Collaboration and _12

Research, Collaboration and Licensing Agreements - Additional Information - Daiichi Sankyo Two (Detail) - USD ($)	May 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 7,860,000	$ 2,054,000	$ 27,667,000	$ 24,094,000
Daiichi Sankyo, Co., Ltd [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					$ 18,000,000
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				0
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				0
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				$ 0
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty agreement term	10 years
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 126,700,000
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 340,000,000
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty percentage earned from sales of product	10.00%
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities	$ 18,000,000
Performance obligation recognized	$ 18,000,000

Research, Collaboration and _13

Research, Collaboration and Licensing Agreements - Additional Information - Janssen (Detail) - USD ($)	Nov. 13, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 7,860,000	$ 2,054,000	$ 27,667,000	$ 24,094,000
Janssen Biotech, Inc. [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities	$ 50,000,000
Performance obligation recognized	50,000,000
Janssen Biotech, Inc. [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				0
Janssen Biotech, Inc. [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Development Milestone [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	282,000,000
Janssen Biotech, Inc. [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				0
Janssen Biotech, Inc. [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Commercial Milestones [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 1,119,000,000
Janssen Biotech, Inc. [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				0
Janssen Biotech, Inc. [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Royalty [Member] | Eligible to Receive [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty agreement term	10 years
Payment for royalty	$ 10,000,000
Royalty payment percentage	1.00%
Janssen Biotech, Inc. [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				$ 0

Research, Collaboration and _14

Research, Collaboration and Licensing Agreements - Additional Information - LEO (Detail) - USD ($)	Oct. 23, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 7,860,000	$ 2,054,000	$ 27,667,000	$ 24,094,000
LEO Pharma [Member] | Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 336,000		1,108,000
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 0
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	0
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Investigational New Drug [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 0
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Research Support Payments [Member] | Project One [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				$ 1,108,000	$ 0
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | First Therapeutic [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty payments on future global net sales	20.00%
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | First Therapeutic [Member] | Maximum [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 74,000,000
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | First Therapeutic [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	157,000,000
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Second Therapeutic [Member] | Maximum [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	86,500,000
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Second Therapeutic [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	157,000,000
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities	5,000,000
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member] | Project One [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligation recognized	$ 5,000,000

Research, Collaboration and _15

Research, Collaboration and Licensing Agreements - Additional Information - BeiGene (Detail)	Nov. 26, 2018USD ($)Agreement	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 7,860,000	$ 2,054,000	$ 27,667,000	$ 24,094,000
Bei Gene [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities		32,941,000		32,941,000		$ 36,471,000
Bei Gene [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				3,530,000
Bei Gene [Member] | Research and License Agreement [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligation recognized						20,000,000
Bei Gene [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Fair value of consideration allocated to a group of contracts that were considered as a single contract						40,000,000
Bei Gene [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Bispecific Therapeutic [Member] | Maximum [Member] | Commercial and Development Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 702,000,000
Bei Gene [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member] | Bispecific Therapeutic [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities						20,000,000
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of agreements | Agreement	3
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				0
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				0
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				0
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | ZW25 Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Fair value of consideration allocated to a single performance obligation	$ 7,100,000
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | ZW49 Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				0
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | ZW25 and ZW49 Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligation recognized						20,000,000
Royalty payments on future global net sales	20.00%
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | ZW25 and ZW49 Agreements [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 390,000,000
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment received						60,000,000
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member] | ZW25 Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligation recognized				3,500,000
Contract liabilities		32,941,000		32,941,000		36,471,000
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member] | ZW49 Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities		$ 32,941,000		$ 32,941,000		$ 36,471,000

Research, Collaboration and _16

Research, Collaboration and Licensing Agreements - Additional Information - Iconic (Detail) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	May 13, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 7,860,000		$ 2,054,000	$ 27,667,000	$ 24,094,000
License Agreement [Member] | Research Support And Supplies Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					$ 0
Iconic Therapeutics Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities						$ 0
Iconic Therapeutics Inc [Member] | Research Support And Supplies Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 24,000			$ 1,029,000
Iconic Therapeutics Inc [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 1,000,000

Leases - Additional Information

Leases - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Lease description	The Company has also entered into a lease for laboratory space in Vancouver, British Columbia that will expire in August 2021. The leases contain rent escalation clauses. The Company entered into a lease on January 25, 2019 in Vancouver to serve as the Company’s future head office. The commencement date of this lease will be no later than September 21, 2021, and has an initial term of ten years, with two five-year extension options.
Cash paid for measurement of operating lease liabilities	$ 1,200
Weighted Average Remaining Lease Term	4 years 3 months 18 days
Operating lease expense	$ 698
Fixed lease payment	657
Variable lease payment	$ 41
BRITISH COLUMBIA
Lease Expiration Date	Aug. 30, 2021
BRITISH COLUMBIA | Leased Laboratory Space [Member]
Lease Expiration Date	Aug. 30, 2021
WASHINGTON
Lease Expiration Date	Feb. 28, 2022
WASHINGTON | Office Space [Member]
Lease Expiration Date	Apr. 30, 2025
Lease description	Effective February 25, 2019, the Company also entered into a lease for office space in Seattle. The commencement date of this lease was July 30, 2019 for a portion of the space and will be no later than April 1, 2020 for the remaining portion of the space.
Operating lease extension period	5 years
Canada, Dollars
Discount Rate	4.60%
United States of America, Dollars
Discount Rate	2.90%

Leases - Schedule of Balance Sh

Leases - Schedule of Balance Sheet Classification of Lease Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Leases [Abstract]
Current portion	$ 912
Long-term portion	5,843
Operating lease liabilities	6,755	$ 3,561
Current portion included in other current liabilities	9		$ 15
Long-term portion included in other long-term liabilities	47		42
Total finance lease liabilities	56		57
Total lease liabilities	$ 6,811		$ 57

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019
Leases [Abstract]
Within 1 year	$ 1,307
1 to 2 years	2,253
2 to 3 years	1,131
3 to 4 years	982
4 to 5 years	1,010
Thereafter	604
Total operating lease payments	7,287
Imputed interest	(532)
Operating lease liabilities	$ 6,755	$ 3,561

Leases - Schedule of Maturiti_2

Leases - Schedule of Maturities of Finance Lease Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Leases [Abstract]
Within 1 year	$ 27
1 to 2 years	22
2 to 3 years	6
3 to 4 years	4
4 to 5 years	2
Total finance lease payments	61
Imputed interest	(5)
Finance lease liabilities	$ 56	$ 57

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Aug. 31, 2016
Contractual Obligation, Fiscal Year Maturity Schedule [Abstract]
Aggregate payment for annual licensing fees	$ 0		$ 12,000
Annual licensing fees payment period	five-year period
Estimated fair value of contingent consideration	$ 992	$ 707